ribavirin has been researched along with Menopause in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernabucci, V; Cammà, C; Cerami, C; Ciancio, A; Critelli, R; Karampatou, A; Petta, S; Rizzetto, M; Sagnelli, C; Strona, S; Todesca, P; Turco, L; Villa, E | 1 |
| Bernabucci, V; Cammà, C; De Maria, N; Di Leo, A; Enea, M; Ferrari, A; Francavilla, A; Gitto, S; Karampatou, A; Lei, B; Losi, L; Rendina, M; Vignoli, P; Villa, E; Vukotic, R | 1 |
2 trial(s) available for ribavirin and Menopause
| Article | Year |
|---|---|
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Logistic Models; Menopause; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Menopause; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; Young Adult | 2012 |